CAR T-cell therapy shows promise in renal cell carcinoma
Findings presented at the 2023 AACR Annual Meeting showed that the allogeneic anti-CD70 CAR T-cell therapy ALLO-316 was safe and induced early signs of antitumor activity in patients with advanced or metastatic clear cell renal cell carcinoma (RCC).
In a recent phase 1 study, a CAR T-cell therapy, called ALLO-316, showed signs of activity against advanced or metastatic clear cell renal cell carcinoma (RCC) in patients who had been previously treated. ALLO-316 was well tolerated by patients with RCC.
Because this was an early phase study that was looking for the best dose of ALLO-316 to use in cancer patients, there were only 18 patients who were assessed for the effectiveness of the treatment. All patients had been previously treated with immunotherapy and/or TKIs. After an average of nearly 8 months follow-up, ALLO-316 controlled the cancer in 89% of patients.
The treatment seemed to work better in patients with the CD70 protein on their T cells. Of the 10 patients who were CD70-positive, 3 patients had a partial response to treatment and the cancer was controlled in all 10 of these patients.
The treatment seemed to be well tolerated with only one patient having to limit their dose because of side effects (severe autoimmune liver disease). Two patients had severe side effects (fainting and fatigue) and one patient died due to respiratory failure from COVID-19infection, which was unrelated to the study treatment.
CD70 is a promising target for CAR T-cell therapy, as it is expressed in up to 80% of patients with RCC and is detected in other malignances; moreover, its expression is restricted in normal tissue.
https://www.urologytimes.com/view/car-t-cell-therapy-shows-promise-in-renal-cell-carcinoma
ارسال به دوستان